What is the appropriate initial dosing, monitoring, and contraindications for prescribing propylthiouracil (PTU) in an adult with newly diagnosed hyperthyroidism, including considerations for severe disease, liver function, and pregnancy?

PTU Prescribing in Adults with Hyperthyroidism

Propylthiouracil should NOT be used as first-line therapy in adults with newly diagnosed hyperthyroidism—methimazole is preferred except in three specific situations: first trimester pregnancy, thyroid storm, or methimazole intolerance. 1, 2

When PTU is Appropriate

PTU use is restricted to:

• First trimester of pregnancy (switch to methimazole in second trimester) 1, 3
• Thyroid storm 1
• Methimazole intolerance in patients refusing radioactive iodine or surgery 1

Initial Dosing

Standard Dosing

• Initial dose: 50-150 mg three times daily (total 150-450 mg/day), depending on hyperthyroidism severity 1, 2
• Severe hyperthyroidism or very large goiters may require 400-900 mg daily initially 2
• Maintenance dose: 50 mg two to three times daily (100-150 mg total) once euthyroid 1, 2

Dosing by Severity

For severe hyperthyroidism (free T4 ≥7 ng/dL), higher initial doses are necessary to achieve control 4. The evidence shows that PTU 300 mg/day is less effective than methimazole 30 mg/day in severe cases, reinforcing that PTU should be avoided when possible 4.

Absolute Contraindications

Do not initiate PTU if: 1

• Baseline absolute neutrophil count <500/mm³
• Liver transaminases >5 times upper limit of normal
• History of PTU-induced liver failure or agranulocytosis
• History of ANCA-positive vasculitis on PTU

Mandatory Baseline Monitoring

Before starting PTU: 1

• Complete blood count with differential (white count, absolute neutrophil count)
• Comprehensive liver panel (ALT, AST, bilirubin, alkaline phosphatase)
• TSH and free T4 (or total T4 and T3)

Ongoing Monitoring Protocol

Thyroid Function

• Every 4-8 weeks until euthyroid on minimal dose 1
• Every 2-3 months once stable 1
• Monitor free T4 and TSH (TSH may remain suppressed initially) 1

Safety Monitoring

Do NOT perform routine CBC or liver function monitoring—these tests do not prevent severe complications due to their rapid, unpredictable onset 1, 2, 5

Instead, implement symptom-based surveillance:

Liver Toxicity Warning Signs

Instruct patients to immediately stop PTU and call if they develop: 1, 2

• Jaundice or dark urine
• Light-colored stools
• Right upper quadrant pain
• Anorexia, nausea, or fatigue
• Pruritus

PTU-induced liver failure can be fatal and occurs unpredictably, most commonly after 4+ months of therapy but can occur with even a single dose 2, 5, 6. The FDA documented 32 cases requiring liver transplantation or resulting in death 1, 2.

Agranulocytosis Warning Signs

Instruct patients to immediately stop PTU and call if they develop: 1, 2

• Fever
• Sore throat or pharyngitis
• Any signs of infection

Obtain urgent CBC with differential during any febrile illness 1. Agranulocytosis occurs in 0.2-0.5% of patients, typically within the first 3 months 2.

Vasculitis Warning Signs

Monitor for: 1, 2

• Joint pain (arthralgias)
• Skin rash
• Hematuria or proteinuria
• Hemoptysis

ANCA-positive vasculitis risk increases with duration of therapy (unlike other adverse effects that occur early) 1, 2.

Pregnancy-Specific Considerations

First Trimester

• PTU is preferred over methimazole due to methimazole's association with choanal/esophageal atresia and aplasia cutis 1, 3
• Use lowest effective dose to maintain free T4 at or slightly above upper limit of normal 1
• Keep TSH suppressed (do not use as sole guide) 1

Second and Third Trimesters

• Switch to methimazole at beginning of second trimester due to PTU hepatotoxicity risk 1, 3
• Conversion ratio: PTU 300 mg ≈ MMI 10-15 mg (20-30:1 potency ratio) 1
• Recheck thyroid function 2 weeks after switching, then every 2-4 weeks 3
• Alternative: Continue PTU with liver enzymes checked every 4 weeks, though this monitoring does not prevent fulminant hepatotoxicity 1

Monitoring in Pregnancy

• Monthly thyroid function tests 1
• Target: Free T4 at or slightly above upper limit of non-pregnant range 1
• Never use block-and-replace therapy in pregnancy 1

Critical Pitfalls to Avoid

1. Using PTU as first-line therapy: Methimazole has superior safety profile except in the three specific situations noted 1, 2

2. Relying on routine lab monitoring: Severe liver injury and agranulocytosis occur too rapidly for scheduled monitoring to prevent complications 2, 5

3. Inadequate patient education: Patients must understand warning symptoms and the need for immediate drug cessation and contact 1, 7

4. Continuing PTU beyond first trimester in pregnancy: Switch to methimazole to reduce maternal hepatotoxicity risk 1, 3

5. Using PTU in children: PTU is contraindicated in pediatrics except when methimazole is not tolerated and surgery/radioactive iodine are inappropriate 2, 5

6. Cross-switching after serious adverse reaction: If agranulocytosis or severe hepatotoxicity occurs with either PTU or methimazole, the other drug is absolutely contraindicated due to cross-reactivity risk 1

Duration of Therapy

• Continue for 12-18 months, then taper if TSH normal 1
• Measure TRAb levels before stopping—normal levels predict higher remission rates 1
• If hyperthyroidism recurs after completing course, strongly consider radioactive iodine or surgery rather than restarting PTU 1